Drug Profile
Research programme: glucocorticoid receptor II antagonists - Corcept Therapeutics
Latest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Corcept Therapeutics
- Class
- Mechanism of Action Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alcoholism; Alzheimer's disease; Amnesia; Amyotrophic lateral sclerosis; Cancer; Obesity; Post-traumatic stress disorders; Prostate cancer; Psychiatric disorders
- Discontinued Muscular dystrophies
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Muscular dystrophies in USA (PO) (Corcept Therapeutics pipeline, February 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Prostate-cancer in USA (PO)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Alcoholism in USA (PO)